Home・Elenco Azioni・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Aperta

SettoreSettore sanitario

39.61 0.35

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

38.85

Massimo

39.61

Metriche Chiave
By Trading Economics
Entrata	43M 75M
Vendite	46M 261M
P/E Media del settore	12.42 57.002
EPS	1.28
Margine di Profitto	28.87
Dipendenti	293
EBITDA	47M 96M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+5.34% upside

Dividendi
By Acuity
Utili prossimi	3 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	210M 2.3B
Apertura precedente	39.26
Chiusura precedente	39.61

Notizie sul Sentiment di mercato

By Acuity

50%

135 / 340 Classifica in Healthcare

Harmony Biosciences Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 ago 2026, 19:21 UTC

Harmony Biosciences Holdings Inc. is trading higher today, continuing its upward trajectory since Monday's close amid broader market trends and rising oil prices.

10 ago 2026, 19:46 UTC

Harmony Biosciences Holdings Inc is trading higher, continuing its upward trend since Friday. The stock remains above its 20-day moving average.

7 ago 2026, 20:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower amid broader market declines and decreasing Treasury yields following recent economic data.

6 ago 2026, 23:51 UTC

Harmony Biosciences Holdings Inc shares declined during after-market hours, struggling to maintain earlier gains amid a lack of specific news to explain the movement.

5 ago 2026, 20:03 UTC

Social Media

Event

News

Harmony Biosciences shares are lower despite new Phase 1 data on BP-205. Truist maintains a Hold rating and raises the price target to $34.

4 ago 2026, 20:04 UTC

Social Media

News

Event

Harmony Biosciences reported strong Q2 earnings of $75.43 million and reaffirmed 2026 revenue guidance, with shares trading sharply higher during the session.

3 ago 2026, 23:11 UTC

Harmony Biosciences shares are higher in after-hours trading, supported by positive sentiment from the Institute for Supply Management's manufacturing PMI report.

1 ago 2026, 00:01 UTC

Shares of Harmony Biosciences Holdings Inc are higher in after-market trading, reflecting notable strength since Friday's close without any specific news driving the move.

31 lug 2026, 23:21 UTC

Harmony Biosciences Holdings Inc. is trading higher during after-market hours, reflecting steady price increases since Friday's close, despite no specific news identified.

28 lug 2026, 18:26 UTC

News

Shares of Harmony Biosciences are lower despite a 30% revenue increase for WAKIX, as market sentiment reflects concerns over potential cash flow erosion.

27 lug 2026, 19:41 UTC

Shares of Harmony Biosciences Holdings Inc. are higher today, breaking from a recent upward trend despite the absence of specific company news.

24 lug 2026, 17:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower today, continuing a decline since Thursday's close, despite earlier reaching a session high.

22 lug 2026, 20:01 UTC

News

Harmony Biosciences Holdings Inc is trading lower despite preliminary Q2 2026 results showing record net product revenue of approximately $261 million, a 30% year-over-year increase.

21 lug 2026, 21:01 UTC

Harmony Biosciences Holdings Inc. shares are lower in after-market trading, diverging from a broader market rebound despite no specific news driving the decline.

Confronto tra pari

Modifica del prezzo

Harmony Biosciences Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

5.34% in crescita

Previsioni per 12 mesi

Media 41.63 USD 5.34%

Alto 55 USD

Basso 30 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

135 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.